For the quarter ending 2026-03-31, ELAB had $8,952,041 increase in cash & cash equivalents over the period. -$3,342,682 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Issuance of promissory note | - | 0 | 0 | 127,300 |
| Purchase of intangible assets | - | 0 | 0 | 6,000 |
| Purchase of investments | 1,435,393 | 224,985 | 568,959 | 995,100 |
| Purchase of equipment | 363,087 | 346,661 | 95,594 | 0 |
| Acquisition of businesses | 2,019,909 | 492,969 | 1,669,787 | - |
| Proceeds from sale of investments | 1,334,780 | 515,973 | 136,307 | 1,109,921 |
| Cash flows used in investing activities | -2,483,609 | -548,642 | -2,198,033 | -18,479 |
| Repayment towards promissory note | 21,250 | - | - | - |
| Equipment financing proceeds | -353,468 | - | - | - |
| Repayment towards equipment financing | 13,049 | - | - | - |
| Proceeds from the pre-paid purchases of equity purchase facility (eloc), net | 14,093,737 | - | - | - |
| Exercise of series a warrants | 0 | 0 | -240,714 | 1,938,772 |
| Issuance of common stock under atm agreement, net | - | -1 | 1,672,104 | - |
| Exercise of replacement warrants, net | - | 0 | 27,415 | 1,484,028 |
| Proceeds from the issuance of common stock and warrants | -1,519,437 | - | - | 1,519,437 |
| Proceeds from the registered direct offering, net | - | 0 | 1,245,306 | - |
| Share issuance costs | -531,290 | - | - | 531,290 |
| Proceeds from the initial pre-paid purchase of eloc, net | - | 0 | 3,990,007 | - |
| Repurchase of shares and warrants | 0 | 0 | 0 | 179 |
| Cash flows provided by financing activities | 14,412,906 | -1 | 5,705,971 | 4,410,768 |
| Effect of exchange rate changes on cash | 2,339 | 414 | 163 | -400 |
| Change in fair value of derivative liabilities | - | -214,167 | - | 0 |
| Bad debt expense | 1,567 | 55,380 | - | - |
| Depreciation and amortization | 173,904 | 59,757 | 35,284 | 1,622 |
| Finance cost | 561,922 | 110,019 | 179,479 | - |
| Share-based compensation | 8,216 | 10,657 | 13,179 | -42,996 |
| Straight-line rent expense | -16,258 | -7,785 | 30,403 | 230 |
| Change in fair value of derivative liabilities | -681,126 | - | - | - |
| Impairment on prepaid expense | - | 500,000 | - | - |
| Non-cash interest expense | 463,421 | 226,841 | 27,081 | - |
| Deferred tax expense | - | 30,972 | - | - |
| Loss on disposal of pp&e | -64,245 | -32,432 | - | - |
| Receivables | -120,049 | 18,783 | -22,662 | 104,473 |
| Prepaid expenses and deposits | 41,296 | 193,571 | -73,883 | -120,999 |
| Inventory | 114,570 | -23,371 | -101,531 | -22,966 |
| Accounts payable and accrued liabilities | 116,488 | 692,218 | 434,809 | -169,268 |
| Due to related parties | -2,928 | 0 | 0 | -397,728 |
| Gain on extinguishment of related-party debt | - | 31,261 | - | - |
| Net loss | -4,967,259 | -2,982,683 | -2,594,320 | -2,170,810 |
| Realized loss (gain) on sale of investments | 23,151 | 283,448 | -25,871 | -371,494 |
| Accretion interest expense | - | - | - | 9,684 |
| Unrealized loss(gain) on investments | 37,587 | -224,481 | -230,461 | 238,899 |
| Research and development costs for intangible assets | 0 | 0 | 0 | 14,358 |
| Gain on termination of intangible asset | 0 | 0 | 0 | 129,613 |
| Loss on the sale of skincare | 0 | 0 | 0 | -39,676 |
| Customer deposits | 0 | 0 | 0 | -20,496 |
| Cash flows used in operating activities | -2,979,595 | -1,750,000 | -1,490,167 | -2,693,714 |
| Increase in cash | 8,952,041 | -2,298,229 | 2,017,934 | 1,698,175 |
| Cash, beginning of period | 5,402,333 | 3,984,453 | 3,984,453 | - |
| Cash, ending of period | 14,354,374 | -2,298,229 | 7,700,562 | - |
PMGC Holdings Inc. (ELAB)
PMGC Holdings Inc. (ELAB)